Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Bibtex

@article{a30ecf36197d4ab38d1ed99d36565fd7,
title = "Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients",
abstract = "Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47{\%}), R-hyper-CVAD (16{\%}), DA-EPOCH-R (11{\%}), R-BFM/GMALL (25{\%}) and other (2{\%}) leading to an overall response rate of 89{\%}. The two-year overall survival and event-free survival were 84{\%} and 80{\%} respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6{\%} but diminished to 0·6{\%} for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95{\%} CI: −0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.",
keywords = "Burkitt lymphoma, immunochemotherapy, prognosis, real-world patients, survival",
author = "Jakobsen, {Lasse H.} and Fredrik Ellin and Smeland, {Knut B.} and Tove W{\"a}sterlid and Christensen, {Jacob H.} and J{\o}rgensen, {Judit M.} and Josefsson, {P{\"a}r L.} and {\O}vlisen, {Andreas K.} and Harald Holte and Blaker, {Yngvild N.} and Grauslund, {Jacob H.} and Jon Bj{\o}rn and Daniel Molin and Ingemar Lagerl{\"o}f and Smedby, {Karin E.} and Katherine Colvin and Gita Thanarajasingam and Maurer, {Matthew J.} and Habermann, {Thomas M.} and Song, {Kevin W.} and Zhu, {Katie Y.} and Gerrie, {Alina S.} and Cheah, {Chan Y.} and El-Galaly, {Tarec C.}",
year = "2020",
doi = "10.1111/bjh.16425",
language = "English",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Federation of European Neuroscience Societies and Blackwell Publishing Ltd",

}